The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.
Immunofluorescence assays are used extensively for the detection of viral antigens, including COVID-19. As a result, the pandemic has increased the demand for immunofluorescence assay products across the globe.
These are fast and simple methods that allow researchers to visualize the effects and dynamics of viral infections. In the current global scenario, such methods represent a crucial tool in preventing and treating these pathogens.
Over the last few decades, the prevalence of chronic diseases has increased significantly across the globe. According to the WHO, by 2020, chronic diseases are estimated to account for 73% of all deaths and 60% of the global burden of diseases.
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571
Diabetes, cancer, infectious diseases, neurological disorders, autoimmune diseases, cardiovascular diseases, lung disorders, severe pancreatitis, and renal failure are major chronic diseases worldwide. According to the American Institute for Cancer Research, an estimated 18.1 million cancer cases were reported worldwide in 2018; this is projected to increase to 29.5 million by 2040.
In immunofluorescence assays, imaging instruments are used to visualize and locate the fluorescently labeled antibodies in a sample. These imaging instruments are expensive as they are equipped with advanced features and functionalities.
The demand for pathology services has increased significantly for clinical applications due to the increasing prevalence of chronic diseases. Histopathology technologies account for the majority of the tests performed on cancer patients.
The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.
The immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate.